0001209191-23-038022.txt : 20230616 0001209191-23-038022.hdr.sgml : 20230616 20230616173150 ACCESSION NUMBER: 0001209191-23-038022 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GAUGLER DARYL CENTRAL INDEX KEY: 0001928278 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 231022455 MAIL ADDRESS: STREET 1: C/O PACIRA BIOSCIENCES, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-14 0 0001396814 Pacira BioSciences, Inc. PCRX 0001928278 GAUGLER DARYL C/O PACIRA BIOSCIENCES 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Operating Officer 0 Common Stock 2023-06-14 4 A 0 10000 0.00 A 31539 D Stock Option (Right to Buy) 38.74 2023-06-14 4 A 0 25000 0.00 A 2033-06-14 Common Stock 25000 25000 D Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams, Attorney-in-Fact 2023-06-16